A transition plan developed for the ENGAGE-AF TIMI 48 trial was associated with reduced excess thrombotic and bleeding events in patients moved from one oral anticoagulant to another. In the ...

Analysis of the ROCKET AF trial shows patients are at high risk for stroke when they stop their anticoagulants, underscoring the importance of anticoagulation coverage during the transition to a ...

Warfarin is associated with higher rates of upper gastrointestinal (GI) bleeding but not overall or lower gastrointestinal bleeding rates compared with direct oral anticoagulants (DOACs ...

Anticoagulants Verseon has submitted the Phase I protocol for its lead precision oral anticoagulant (PROAC) candidate, VE-1902, and expects to start first-in-human trials in Q3 2018.

Biotechnology company Medicines Co. <MDCO.O> said it reacquired all development, commercial and distribution rights in Europe for Angiox, its anticoagulant used in angioplasty, from Nycomed.